Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Daily Top 10 COVID-19 papers

DEU | ENG | ESP | FRA | ITA | POR | TUR | VNM


  Alzheimer's Disease

  Free Subscription


Articles published in Neurology

Retrieve available abstracts of 152 articles:
HTML format



Single Articles


    May 2020
  1. MATTSSON-CARLGREN N, Leuzy A, Janelidze S, Palmqvist S, et al
    The implications of different approaches to define AT(N) in Alzheimer disease.
    Neurology. 2020 May 12. pii: WNL.0000000000009485.
    PubMed     Abstract available


  2. BERNATH MM, Bhattacharyya S, Nho K, Barupal DK, et al
    Serum triglycerides in Alzheimer disease: Relation to neuroimaging and CSF biomarkers.
    Neurology. 2020 May 1. pii: WNL.0000000000009436.
    PubMed     Abstract available


    April 2020
  3. SARYCHEVA T, Lavikainen P, Taipale H, Tiihonen J, et al
    Antiepileptic drug use and mortality among community-dwelling persons with Alzheimer disease.
    Neurology. 2020 Apr 23. pii: WNL.0000000000009435.
    PubMed     Abstract available


  4. VILAPLANA E, Rodriguez-Vieitez E, Ferreira D, Montal V, et al
    Cortical microstructural correlates of astrocytosis in autosomal dominant Alzheimer disease.
    Neurology. 2020 Apr 14. pii: WNL.0000000000009405.
    PubMed     Abstract available


    March 2020
  5. BREITNER J, Meyer PF
    Author response: INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease.
    Neurology. 2020;94:594.
    PubMed    


  6. ASHFORD JW
    Reader response: INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease.
    Neurology. 2020;94:593-594.
    PubMed    


  7. GANESH A, Galetta S
    Editors' note: INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease.
    Neurology. 2020;94:593.
    PubMed    


  8. TERADA T, Obi T, Bunai T, Matsudaira T, et al
    In vivo mitochondrial and glycolytic impairments in patients with Alzheimer disease.
    Neurology. 2020 Mar 5. pii: WNL.0000000000009249.
    PubMed     Abstract available


  9. SWERDLOW RH
    Mitochondria in Alzheimer brains: A PET project shows complex changes.
    Neurology. 2020 Mar 5. pii: WNL.0000000000009236.
    PubMed    


    February 2020
  10. FERREIRA D, Nordberg A, Westman E
    Biological subtypes of Alzheimer disease: A systematic review and meta-analysis.
    Neurology. 2020 Feb 11. pii: WNL.0000000000009058.
    PubMed     Abstract available


  11. HAAKSMA ML, Eriksdotter M, Rizzuto D, Leoutsakos JS, et al
    Survival time tool to guide care planning in people with dementia.
    Neurology. 2020;94:e538-e548.
    PubMed     Abstract available


    January 2020
  12. RESENDE EPF, Nolan AL, Petersen C, Ehrenberg AJ, et al
    Language and spatial dysfunction in Alzheimer disease with white matter thorn-shaped astrocytes: Astrocytic tau, cognitive function, and Alzheimer disease.
    Neurology. 2020 Jan 30. pii: WNL.0000000000008937.
    PubMed     Abstract available


  13. HOLLAND TM, Agarwal P, Wang Y, Leurgans SE, et al
    Dietary flavonols and risk of Alzheimer dementia.
    Neurology. 2020 Jan 29. pii: WNL.0000000000008981.
    PubMed     Abstract available


  14. MARTERSTECK A, Sridhar J, Rader B, Coventry C, et al
    Differential neurocognitive network perturbation in amnestic and aphasic Alzheimer disease.
    Neurology. 2020 Jan 22. pii: WNL.0000000000008960.
    PubMed     Abstract available


  15. ESPAY AJ, Vizcarra JA, Marsili L, Lang AE, et al
    Author response: Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases.
    Neurology. 2020;94:144-145.
    PubMed    


  16. NELSON P
    Reader response: Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases.
    Neurology. 2020;94:143-144.
    PubMed    


  17. SIEGLER JE 3RD, Galetta S
    Editors' note: Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases.
    Neurology. 2020;94:143.
    PubMed    


  18. WAZIRY R, Chibnik LB, Bos D, Ikram MK, et al
    Risk of hemorrhagic and ischemic stroke in patients with Alzheimer disease: A synthesis of the literature.
    Neurology. 2020 Jan 16. pii: WNL.0000000000008924.
    PubMed     Abstract available


  19. YU L, Boyle PA, Dawe RJ, Bennett DA, et al
    Contribution of TDP and hippocampal sclerosis to hippocampal volume loss in older-old persons.
    Neurology. 2020;94:e142-e152.
    PubMed     Abstract available


    December 2019
  20. SOLDAN A, Pettigrew C, Zhu Y, Wang MC, et al
    White matter hyperintensities and CSF Alzheimer disease biomarkers in preclinical Alzheimer disease.
    Neurology. 2019 Dec 30. pii: WNL.0000000000008864.
    PubMed     Abstract available


  21. CAVEDO E, Lista S, Houot M, Vergallo A, et al
    Plasma tau correlates with basal forebrain atrophy rates in people at risk for Alzheimer disease.
    Neurology. 2019 Dec 4. pii: WNL.0000000000008696.
    PubMed     Abstract available


    November 2019
  22. HONDA T, Ohara T, Shinohara M, Hata J, et al
    Serum elaidic acid concentration and risk of dementia: The Hisayama Study.
    Neurology. 2019;93:e2053-e2064.
    PubMed     Abstract available


  23. GRAFF-RADFORD J, Gunter JL, Jones DT, Przybelski SA, et al
    Cerebrospinal fluid dynamics disorders: Relationship to Alzheimer biomarkers and cognition.
    Neurology. 2019 Nov 12. pii: WNL.0000000000008616.
    PubMed     Abstract available


  24. WEINTRAUB S, Teylan M, Rader B, Chan KCG, et al
    APOE is a correlate of phenotypic heterogeneity in Alzheimer disease in a national cohort.
    Neurology. 2019 Nov 8. pii: WNL.0000000000008666.
    PubMed     Abstract available


    October 2019
  25. NETH BJ
    Right brain: Art and the restoration of identity in dementia.
    Neurology. 2019;93:719-721.
    PubMed    


  26. CHONG JSX, Jang H, Kim HJ, Ng KK, et al
    Amyloid and cerebrovascular burden divergently influence brain functional network changes over time.
    Neurology. 2019;93:e1514-e1525.
    PubMed     Abstract available


  27. SCHNEIDER LS, Geffen Y, Rabinowitz J, Thomas RG, et al
    Low-dose ladostigil for mild cognitive impairment: A phase 2 placebo-controlled clinical trial.
    Neurology. 2019;93:e1474-e1484.
    PubMed     Abstract available


  28. MIRZA SS, Saeed U, Knight J, Ramirez J, et al
    APOE varepsilon4, white matter hyperintensities, and cognition in Alzheimer and Lewy body dementia.
    Neurology. 2019 Oct 1. pii: WNL.0000000000008377.
    PubMed     Abstract available


    August 2019

  29. INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease.
    Neurology. 2019;93:371.
    PubMed    


  30. BENDLIN BB, Zetterberg H
    Screening with a high precision blood-based assay for Alzheimer disease.
    Neurology. 2019 Aug 1. pii: WNL.0000000000008080.
    PubMed    


    July 2019
  31. WOLTERS FJ, Zonneveld HI, Licher S, Cremers LGM, et al
    Hemoglobin and anemia in relation to dementia risk and accompanying changes on brain MRI.
    Neurology. 2019 Jul 31. pii: WNL.0000000000008003.
    PubMed     Abstract available


  32. QIU Y, Jacobs DM, Messer K, Salmon DP, et al
    Cognitive heterogeneity in probable Alzheimer disease: Clinical and neuropathologic features.
    Neurology. 2019 Jul 18. pii: WNL.0000000000007967.
    PubMed     Abstract available



  33. Clinical phenotype, atrophy, and small vessel disease in APOEepsilon2 carriers with Alzheimer disease.
    Neurology. 2019;93:135.
    PubMed    


  34. INSEL PS, Weiner M, Mackin RS, Mormino E, et al
    Determining clinically meaningful decline in preclinical Alzheimer disease.
    Neurology. 2019 Jul 9. pii: WNL.0000000000007831.
    PubMed     Abstract available


  35. HAN SD, Shinotoh H
    The search for meaning in preclinical Alzheimer disease clinical trials.
    Neurology. 2019 Jul 9. pii: WNL.0000000000007817.
    PubMed    


  36. BISCHOF GN, Jacobs HIL
    Subthreshold amyloid and its biological and clinical meaning: Long way ahead.
    Neurology. 2019;93:72-79.
    PubMed     Abstract available


  37. VAN LOENHOUD AC, van der Flier WM, Wink AM, Dicks E, et al
    Cognitive reserve and clinical progression in Alzheimer disease: A paradoxical relationship.
    Neurology. 2019 Jul 2. pii: WNL.0000000000007821.
    PubMed     Abstract available


    June 2019
  38. TAGHDIRI F, Multani N, Tarazi A, Naeimi SA, et al
    Elevated cerebrospinal fluid total tau in former professional athletes with multiple concussions.
    Neurology. 2019;92:e2717-e2726.
    PubMed     Abstract available


    May 2019
  39. VERMUNT L, van Paasen AJL, Teunissen CE, Scheltens P, et al
    Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal.
    Neurology. 2019 May 8. pii: WNL.0000000000007609.
    PubMed     Abstract available


    April 2019
  40. KARCESKI S, Karceski S
    Can naproxen slow the progression of Alzheimer disease?
    Neurology. 2019;92:e2181-e2184.
    PubMed    


  41. KNOPMAN DS, Petersen RC, Jack CR Jr
    A brief history of "Alzheimer disease": Multiple meanings separated by a common name.
    Neurology. 2019 Apr 26. pii: WNL.0000000000007583.
    PubMed     Abstract available


  42. ERICKSON CM, Schultz SA, Oh JM, Darst BF, et al
    KLOTHO heterozygosity attenuates APOE4-related amyloid burden in preclinical AD.
    Neurology. 2019;92:e1878-e1889.
    PubMed     Abstract available


  43. ARVANITAKIS Z, Capuano AW
    Author response: Late-life blood pressure association with cerebrovascular and Alzheimer disease pathology.
    Neurology. 2019;92:732.
    PubMed    


  44. LATTANZI S, Silvestrini M
    Reader response: Late-life blood pressure association with cerebrovascular and Alzheimer disease pathology.
    Neurology. 2019;92:731.
    PubMed    


  45. SIEGLER JE 3RD, Galetta S
    Editors' note: Late-life blood pressure association with cerebrovascular and Alzheimer disease pathology.
    Neurology. 2019;92:731.
    PubMed    


  46. MEYER PF, Tremblay-Mercier J, Leoutsakos J, Madjar C, et al
    INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease.
    Neurology. 2019 Apr 5. pii: WNL.0000000000007232.
    PubMed     Abstract available


  47. HERSHEY LA, Lipton RB
    Naproxen for presymptomatic Alzheimer disease: Is this the end, or shall we try again?
    Neurology. 2019 Apr 5. pii: WNL.0000000000007233.
    PubMed    


  48. KANG SW, Jeon S, Yoo HS, Chung SJ, et al
    Effects of Lewy body disease and Alzheimer disease on brain atrophy and cognitive dysfunction.
    Neurology. 2019 Apr 3. pii: WNL.0000000000007373.
    PubMed     Abstract available


  49. SOLDAN A, Pettigrew C, Fagan AM, Schindler SE, et al
    ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes.
    Neurology. 2019;92:e1567-e1579.
    PubMed     Abstract available


    March 2019
  50. SATHYAN S, Wang T, Ayers E, Verghese J, et al
    Genetic basis of motoric cognitive risk syndrome in the Health and Retirement Study.
    Neurology. 2019;92:e1427-e1434.
    PubMed     Abstract available


  51. CANNON-ALBRIGHT LA, Foster NL, Schliep K, Farnham JM, et al
    Relative risk for Alzheimer disease based on complete family history.
    Neurology. 2019 Mar 13. pii: WNL.0000000000007231.
    PubMed     Abstract available


  52. VAN HARTEN AC
    Longevity gene KLOTHO may play a role in Alzheimer disease.
    Neurology. 2019 Mar 13. pii: WNL.0000000000007302.
    PubMed    


  53. VOS SJB, Duara R
    The prognostic value of ATN Alzheimer biomarker profiles in cognitively normal individuals.
    Neurology. 2019 Mar 6. pii: WNL.0000000000007223.
    PubMed    


  54. MESULAM MM, Lalehzari N, Rahmani F, Ohm D, et al
    Cortical cholinergic denervation in primary progressive aphasia with Alzheimer pathology.
    Neurology. 2019 Mar 6. pii: WNL.0000000000007247.
    PubMed     Abstract available


  55. PRESSMAN PS, Gola K, Shdo SM, Miller BL, et al
    Relative preservation of facial expression recognition in posterior cortical atrophy.
    Neurology. 2019;92:e1064-e1071.
    PubMed     Abstract available


    February 2019
  56. FEMMINELLA GD, Dani M, Wood M, Fan Z, et al
    Microglial activation in early Alzheimer trajectory is associated with higher gray matter volume.
    Neurology. 2019 Feb 22. pii: WNL.0000000000007133.
    PubMed     Abstract available


  57. WILSON RS, Yang J, Yu L, Leurgans SE, et al
    Postmortem neurodegenerative markers and trajectories of decline in cognitive systems.
    Neurology. 2019;92:e831-e840.
    PubMed     Abstract available


  58. MORAN C, Beare R, Wang W, Callisaya M, et al
    Type 2 diabetes mellitus, brain atrophy, and cognitive decline.
    Neurology. 2019;92:e823-e830.
    PubMed     Abstract available


  59. BUCHMAN AS, Yu L, Wilson RS, Lim A, et al
    Physical activity, common brain pathologies, and cognition in community-dwelling older adults.
    Neurology. 2019;92:e811-e822.
    PubMed     Abstract available


  60. ESPAY AJ, Vizcarra JA, Marsili L, Lang AE, et al
    Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases.
    Neurology. 2019;92:329-337.
    PubMed     Abstract available


    January 2019
  61. WHITWELL JL, Martin PR, Duffy JR, Clark HM, et al
    The influence of beta-amyloid on [(18)F]AV-1451 in semantic variant of primary progressive aphasia.
    Neurology. 2019 Jan 11. pii: WNL.0000000000006913.
    PubMed     Abstract available


  62. OSSENKOPPELE R, Smith R, Ohlsson T, Strandberg O, et al
    Associations between tau, Abeta, and cortical thickness with cognition in Alzheimer disease.
    Neurology. 2019 Jan 9. pii: WNL.0000000000006875.
    PubMed     Abstract available


  63. KANTARCI K, Jicha GA
    Development of (1)H MRS biomarkers for tracking early predementia Alzheimer disease.
    Neurology. 2019 Jan 4. pii: WNL.0000000000006839.
    PubMed    


    December 2018
  64. HARA Y, McKeehan N, Fillit HM
    Translating the biology of aging into novel therapeutics for Alzheimer disease.
    Neurology. 2018 Dec 7. pii: WNL.0000000000006745.
    PubMed     Abstract available


    October 2018
  65. GROOT C, Sudre CH, Barkhof F, Teunissen CE, et al
    Clinical phenotype, atrophy, and small vessel disease in APOEepsilon2 carriers with Alzheimer disease.
    Neurology. 2018 Oct 19. pii: WNL.0000000000006503.
    PubMed     Abstract available


  66. KORK F, Jankowski J, Goswami A, Weis J, et al
    Golgin A4 in CSF and granulovacuolar degenerations of Alzheimer patients.
    Neurology. 2018 Oct 10. pii: WNL.0000000000006457.
    PubMed     Abstract available


    September 2018
  67. BRICKMAN AM, Tosto G, Gutierrez J, Andrews H, et al
    An MRI measure of degenerative and cerebrovascular pathology in Alzheimer disease.
    Neurology. 2018 Sep 14. pii: WNL.0000000000006310.
    PubMed     Abstract available


  68. MCDADE E, Wang G, Gordon BA, Hassenstab J, et al
    Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease.
    Neurology. 2018 Sep 14. pii: WNL.0000000000006277.
    PubMed     Abstract available


  69. BENNETT DA
    An MRI biomarker of mixed pathology.
    Neurology. 2018 Sep 14. pii: WNL.0000000000006305.
    PubMed    


    August 2018
  70. DICKSON DW, Heckman MG, Murray ME, Soto AI, et al
    APOE epsilon4 is associated with severity of Lewy body pathology independent of Alzheimer pathology.
    Neurology. 2018 Aug 24. pii: WNL.0000000000006212.
    PubMed     Abstract available


  71. PETERSEN RC
    How early can we diagnose Alzheimer disease (and is it sufficient)? The 2017 Wartenberg lecture.
    Neurology. 2018 Aug 8. pii: WNL.0000000000006088.
    PubMed     Abstract available


  72. ASCHENBRENNER AJ, Gordon BA, Benzinger TLS, Morris JC, et al
    Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease.
    Neurology. 2018 Aug 1. pii: WNL.0000000000006075.
    PubMed     Abstract available


    July 2018

  73. Age-dependent white matter inflammation and cognitive impairment in the TgAPP21 rat model of Alzheimer disease.
    Neurology. 2018;91:242.
    PubMed    


  74. JANELIDZE S, Mattsson N, Stomrud E, Lindberg O, et al
    CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease.
    Neurology. 2018 Jul 27. pii: WNL.0000000000006082.
    PubMed     Abstract available


  75. JANG H, Bae JB, Dardiotis E, Scarmeas N, et al
    Differential effects of completed and incomplete pregnancies on the risk of Alzheimer disease.
    Neurology. 2018 Jul 18. pii: WNL.0000000000006000.
    PubMed     Abstract available


  76. ARVANITAKIS Z, Capuano AW, Lamar M, Shah RC, et al
    Late-life blood pressure association with cerebrovascular and Alzheimer disease pathology.
    Neurology. 2018 Jul 11. pii: WNL.0000000000005951.
    PubMed     Abstract available


    June 2018
  77. STRAIN JF, Smith RX, Beaumont H, Roe CM, et al
    Loss of white matter integrity reflects tau accumulation in Alzheimer disease defined regions.
    Neurology. 2018 Jun 29. pii: WNL.0000000000005864.
    PubMed     Abstract available


  78. MERLUZZI AP, Carlsson CM, Johnson SC, Schindler SE, et al
    Neurodegeneration, synaptic dysfunction, and gliosis are phenotypic of Alzheimer dementia.
    Neurology. 2018 Jun 29. pii: WNL.0000000000005901.
    PubMed     Abstract available


  79. BENARROCH EE
    Glutamatergic synaptic plasticity and dysfunction in Alzheimer disease: Emerging mechanisms.
    Neurology. 2018 Jun 13. pii: WNL.0000000000005807.
    PubMed    


    April 2018
  80. PASSAMONTI L, Rodriguez PV, Hong YT, Allinson KSJ, et al
    [(11)C]PK11195 binding in Alzheimer disease and progressive supranuclear palsy.
    Neurology. 2018 Apr 27. pii: WNL.0000000000005610.
    PubMed     Abstract available


  81. CUMMINGS JL, Cohen S, van Dyck CH, Brody M, et al
    ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease.
    Neurology. 2018 Apr 25. pii: WNL.0000000000005550.
    PubMed     Abstract available


  82. BERTI V, Walters M, Sterling J, Quinn CG, et al
    Mediterranean diet and 3-year Alzheimer brain biomarker changes in middle-aged adults.
    Neurology. 2018 Apr 13. pii: WNL.0000000000005527.
    PubMed     Abstract available


  83. KERN S, Zetterberg H, Kern J, Zettergren A, et al
    Prevalence of preclinical Alzheimer disease: Comparison of current classification systems.
    Neurology. 2018 Apr 13. pii: WNL.0000000000005476.
    PubMed     Abstract available


    March 2018
  84. ARENAZA-URQUIJO EM, Vemuri P
    Resistance vs resilience to Alzheimer disease: Clarifying terminology for preclinical studies.
    Neurology. 2018 Mar 28. pii: WNL.0000000000005303.
    PubMed     Abstract available


    February 2018
  85. BENNETT DA, Gordon BA
    Alzheimer disease biomarkers and synucleinopathy.
    Neurology. 2018 Feb 21. pii: WNL.0000000000005171.
    PubMed    


  86. MENDES A, Bertrand A, Lamari F, Colliot O, et al
    Cerebral microbleeds and CSF Alzheimer biomarkers in primary progressive aphasias.
    Neurology. 2018 Feb 14. pii: WNL.0000000000005165.
    PubMed     Abstract available


  87. JONES DT, Knopman DS, Graff-Radford J, Syrjanen JA, et al
    In vivo (18)F-AV-1451 tau-PET signal in MAPT mutation carriers varies by expected tau isoforms.
    Neurology. 2018 Feb 9. pii: WNL.0000000000005117.
    PubMed     Abstract available


  88. BOTHA H, Mantyh WG, Graff-Radford J, Machulda MM, et al
    Tau-negative amnestic dementia masquerading as Alzheimer disease dementia.
    Neurology. 2018 Feb 7. pii: WNL.0000000000005124.
    PubMed     Abstract available


  89. DAY GS, Gordon BA, Perrin RJ, Cairns NJ, et al
    In vivo [(18)F]-AV-1451 tau-PET imaging in sporadic Creutzfeldt-Jakob disease.
    Neurology. 2018 Feb 7. pii: WNL.0000000000005064.
    PubMed     Abstract available


  90. KNOPMAN DS
    Sifting through a failed Alzheimer trial: What biomarkers tell us about what happened.
    Neurology. 2018 Feb 2. pii: WNL.0000000000005073.
    PubMed    


    January 2018
  91. AISEN PS
    Author response: A phase 3 trial of IV immunoglobulin for Alzheimer disease.
    Neurology. 2018;90:145.
    PubMed    


  92. PIAZZA F
    Reader response: A phase 3 trial of IV immunoglobulin for Alzheimer disease.
    Neurology. 2018;90:144-145.
    PubMed    


  93. KARAM C, Griggs RC
    Editors' note: A phase 3 trial of IV immunoglobulin for Alzheimer disease.
    Neurology. 2018;90:144.
    PubMed    


  94. MATTSSON N, Smith R, Strandberg O, Palmqvist S, et al
    Comparing (18)F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease.
    Neurology. 2018 Jan 10. pii: WNL.0000000000004887.
    PubMed     Abstract available


    December 2017
  95. WILLIAMS DM, Karlsson IK, Pedersen NL, Hagg S, et al
    Circulating insulin-like growth factors and Alzheimer disease: A mendelian randomization study.
    Neurology. 2017 Dec 27. pii: WNL.0000000000004854.
    PubMed     Abstract available


  96. YASAR S, Whitmer R
    Statin use and risk of Alzheimer disease: A new view on an old relationship.
    Neurology. 2017 Dec 15. pii: WNL.0000000000004837.
    PubMed    


  97. SINYAVSKAYA L, Gauthier S, Renoux C, Dell'Aniello S, et al
    Comparative effect of statins on the risk of incident Alzheimer disease.
    Neurology. 2017 Dec 15. pii: WNL.0000000000004818.
    PubMed     Abstract available


  98. GROOT C, van Loenhoud AC, Barkhof F, van Berckel BNM, et al
    Differential effects of cognitive reserve and brain reserve on cognition in Alzheimer disease.
    Neurology. 2017 Dec 13. pii: WNL.0000000000004802.
    PubMed     Abstract available


  99. GONNEAUD J, Arenaza-Urquijo EM, Mezenge F, Landeau B, et al
    Increased florbetapir binding in the temporal neocortex from age 20 to 60 years.
    Neurology. 2017;89:2438-2446.
    PubMed     Abstract available


    November 2017
  100. GROTHE MJ, Barthel H, Sepulcre J, Dyrba M, et al
    In vivo staging of regional amyloid deposition.
    Neurology. 2017;89:2031-2038.
    PubMed     Abstract available


  101. CORRIVEAU RA, Koroshetz WJ, Gladman JT, Jeon S, et al
    Alzheimer's Disease-Related Dementias Summit 2016: National research priorities.
    Neurology. 2017 Nov 8. pii: 10.1212/WNL.0000000000004717.
    PubMed     Abstract available


    October 2017
  102. GAUTHIER S, Ng KP, Pascoal TA, Mathotaarachchi S, et al
    Author response: Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease.
    Neurology. 2017;89:1931.
    PubMed    


  103. LANDIN-ROMERO R, Kumfor F
    Letter re: Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease.
    Neurology. 2017;89:1931.
    PubMed    


  104. RISACHER SL, Anderson WH, Charil A, Castelluccio PF, et al
    Alzheimer disease brain atrophy subtypes are associated with cognition and rate of decline.
    Neurology. 2017 Oct 25. pii: 10.1212/WNL.0000000000004670.
    PubMed     Abstract available


  105. WESTON PSJ, Poole T, Ryan NS, Nair A, et al
    Serum neurofilament light in familial Alzheimer disease: A marker of early neurodegeneration.
    Neurology. 2017 Oct 25. pii: 10.1212/WNL.0000000000004667.
    PubMed     Abstract available


  106. FILIPPI M, Basaia S, Canu E, Imperiale F, et al
    Brain network connectivity differs in early-onset neurodegenerative dementia.
    Neurology. 2017;89:1764-1772.
    PubMed     Abstract available


  107. BRENOWITZ WD, Hubbard RA, Keene CD, Hawes SE, et al
    Mixed neuropathologies and associations with domain-specific cognitive decline.
    Neurology. 2017;89:1773-1781.
    PubMed     Abstract available


  108. CHETELAT G, Murray ME
    Amyloid PET scan: Staging beyond reading?
    Neurology. 2017 Oct 18. pii: 10.1212/WNL.0000000000004678.
    PubMed    


  109. KIEBOOM BCT, Licher S, Wolters FJ, Ikram MK, et al
    Serum magnesium is associated with the risk of dementia.
    Neurology. 2017;89:1716-1722.
    PubMed     Abstract available


  110. ROBERTS RO, Knopman DS, Syrjanen JA, Aakre JA, et al
    Weighting and standardization of frequencies to determine prevalence of AD imaging biomarkers.
    Neurology. 2017 Oct 13. pii: 10.1212/WNL.0000000000004652.
    PubMed     Abstract available


  111. GASBY D
    Alzheimer dementia's other victim: The spouse.
    Neurology. 2017 Oct 6. pii: 10.1212/WNL.0000000000004638.
    PubMed    


  112. WEINER MW, Crane PK, Montine TJ, Bennett DA, et al
    Traumatic brain injury may not increase the risk of Alzheimer disease.
    Neurology. 2017 Oct 4. pii: 10.1212/WNL.0000000000004608.
    PubMed     Abstract available


    September 2017
  113. MEDAGLIA JD, Huang W, Segarra S, Olm C, et al
    Brain network efficiency is influenced by the pathologic source of corticobasal syndrome.
    Neurology. 2017;89:1373-1381.
    PubMed     Abstract available


  114. CASALETTO KB, Elahi FM, Bettcher BM, Neuhaus J, et al
    Neurogranin, a synaptic protein, is associated with memory independent of Alzheimer biomarkers.
    Neurology. 2017 Sep 22. pii: 10.1212/WNL.0000000000004569.
    PubMed     Abstract available


  115. NORTON DJ, Amariglio R, Protas H, Chen K, et al
    Subjective memory complaints in preclinical autosomal dominant Alzheimer disease.
    Neurology. 2017 Sep 6. pii: 10.1212/WNL.0000000000004533.
    PubMed     Abstract available


    August 2017
  116. MOSCONI L, Berti V, Quinn C, McHugh P, et al
    Sex differences in Alzheimer risk: Brain imaging of endocrine vs chronologic aging.
    Neurology. 2017 Aug 30. pii: 10.1212/WNL.0000000000004425.
    PubMed     Abstract available



  117. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease.
    Neurology. 2017;89:980.
    PubMed    


  118. SMITH R, Scholl M, Widner H, van Westen D, et al
    In vivo retention of 18F-AV-1451 in corticobasal syndrome.
    Neurology. 2017;89:845-853.
    PubMed     Abstract available


  119. LI G, Mayer CL, Morelli D, Millard SP, et al
    Effect of simvastatin on CSF Alzheimer disease biomarkers in cognitively normal adults.
    Neurology. 2017 Aug 18. pii: 10.1212/WNL.0000000000004392.
    PubMed     Abstract available


    July 2017
  120. BENUSSI A, Di Lorenzo F, Dell'Era V, Cosseddu M, et al
    Transcranial magnetic stimulation distinguishes Alzheimer disease from frontotemporal dementia.
    Neurology. 2017 Jul 26. pii: 10.1212/WNL.0000000000004232.
    PubMed     Abstract available


  121. DONADIO V, Incensi A, Rizzo G, Capellari S, et al
    A new potential biomarker for dementia with Lewy bodies: Skin nerve alpha-synuclein deposits.
    Neurology. 2017;89:318-326.
    PubMed     Abstract available


  122. LAFAILLE-MAGNAN ME, Poirier J, Etienne P, Tremblay-Mercier J, et al
    Odor identification as a biomarker of preclinical AD in older adults at risk.
    Neurology. 2017;89:327-335.
    PubMed     Abstract available


  123. SPIRA AP, Ju YS
    Self-reported sleep and Alzheimer disease CSF biomarkers: A wake-up call.
    Neurology. 2017 Jul 5. pii: 10.1212/WNL.0000000000004189.
    PubMed    


  124. MOFFAT SD
    Author response: Long-term cortisol measures predict Alzheimer disease risk.
    Neurology. 2017;89:106.
    PubMed    


  125. LATTANZI S, Silvestrini M
    Letter re: Long-term cortisol measures predict Alzheimer disease risk.
    Neurology. 2017;89:106.
    PubMed    


    June 2017
  126. ZHAN X
    Author response: Gram-negative bacterial molecules associate with Alzheimer disease pathology.
    Neurology. 2017;88:2338.
    PubMed    


  127. MENTE K
    Letter re: Gram-negative bacterial molecules associate with Alzheimer disease pathology.
    Neurology. 2017;88:2338.
    PubMed    


  128. BUCKLEY RF, Schultz AP, Hedden T, Papp KV, et al
    Functional network integrity presages cognitive decline in preclinical Alzheimer disease.
    Neurology. 2017 Jun 7. pii: 10.1212/WNL.0000000000004059.
    PubMed     Abstract available


  129. ALCOLEA D, Vilaplana E, Suarez-Calvet M, Illan-Gala I, et al
    CSF sAPPbeta, YKL-40, and neurofilament light in frontotemporal lobar degeneration.
    Neurology. 2017 Jun 7. pii: 10.1212/WNL.0000000000004088.
    PubMed     Abstract available


    May 2017
  130. GIANNINI LAA, Irwin DJ, McMillan CT, Ash S, et al
    Clinical marker for Alzheimer disease pathology in logopenic primary progressive aphasia.
    Neurology. 2017 May 17. pii: 10.1212/WNL.0000000000004034.
    PubMed     Abstract available


  131. BOOTS EA, Schultz SA, Clark LR, Racine AM, et al
    BDNF Val66Met predicts cognitive decline in the Wisconsin Registry for Alzheimer's Prevention.
    Neurology. 2017 May 3. pii: 10.1212/WNL.0000000000003980.
    PubMed     Abstract available


    April 2017
  132. SCHULTZ SA, Boots EA, Darst BF, Zetterberg H, et al
    Cardiorespiratory fitness alters the influence of a polygenic risk score on biomarkers of AD.
    Neurology. 2017;88:1650-1658.
    PubMed     Abstract available


  133. NG KP, Pascoal TA, Mathotaarachchi S, Chung CO, et al
    Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease.
    Neurology. 2017 Apr 12. pii: 10.1212/WNL.0000000000003916.
    PubMed     Abstract available


  134. PETERSEN RC, Thomas RG, Aisen PS, Mohs RC, et al
    Randomized controlled trials in mild cognitive impairment: Sources of variability.
    Neurology. 2017 Apr 5. pii: 10.1212/WNL.0000000000003907.
    PubMed     Abstract available


  135. RELKIN NR, Thomas RG, Rissman RA, Brewer JB, et al
    A phase 3 trial of IV immunoglobulin for Alzheimer disease.
    Neurology. 2017 Apr 5. pii: 10.1212/WNL.0000000000003904.
    PubMed     Abstract available


    March 2017
  136. PAPP KV, Rentz DM, Mormino EC, Schultz AP, et al
    Cued memory decline in biomarker-defined preclinical Alzheimer disease.
    Neurology. 2017 Mar 10. pii: 10.1212/WNL.0000000000003812.
    PubMed     Abstract available


    February 2017
  137. DAY GS, Lim TS, Hassenstab J, Goate AM, et al
    Differentiating cognitive impairment due to corticobasal degeneration and Alzheimer disease.
    Neurology. 2017 Feb 24. pii: 10.1212/WNL.0000000000003770.
    PubMed     Abstract available


  138. TOSTO G, Bird TD, Tsuang D, Bennett DA, et al
    Polygenic risk scores in familial Alzheimer disease.
    Neurology. 2017 Feb 17. pii: 10.1212/WNL.0000000000003734.
    PubMed     Abstract available


  139. IMTIAZ B, Tuppurainen M, Rikkonen T, Kivipelto M, et al
    Postmenopausal hormone therapy and Alzheimer disease: A prospective cohort study.
    Neurology. 2017 Feb 15. pii: 10.1212/WNL.0000000000003696.
    PubMed     Abstract available


  140. CHEN J, Yu JT, Wojta K, Wang HF, et al
    Genome-wide association study identifies MAPT locus influencing human plasma tau levels.
    Neurology. 2017;88:669-676.
    PubMed     Abstract available


  141. FRANZMEIER N, Duering M, Weiner M, Dichgans M, et al
    Left frontal cortex connectivity underlies cognitive reserve in prodromal Alzheimer disease.
    Neurology. 2017 Feb 10. pii: 10.1212/WNL.0000000000003711.
    PubMed     Abstract available


  142. KREISL WC, Lawrence R, Page E, Teich AF, et al
    11C-PBR28 PET detects translocator protein in a patient with astrocytoma and Alzheimer disease.
    Neurology. 2017 Feb 8. pii: 10.1212/WNL.0000000000003693.
    PubMed    


    January 2017
  143. FEDOROVA TD, Seidelin LB, Knudsen K, Schacht AC, et al
    Decreased intestinal acetylcholinesterase in early Parkinson disease: An 11C-donepezil PET study.
    Neurology. 2017 Jan 18. pii: 10.1212/WNL.0000000000003633.
    PubMed     Abstract available


  144. THOMAS AJ, Attems J, Colloby SJ, O'Brien JT, et al
    Autopsy validation of 123I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB.
    Neurology. 2017;88:276-283.
    PubMed     Abstract available


    December 2016
  145. ENNIS GE, An Y, Resnick SM, Ferrucci L, et al
    Long-term cortisol measures predict Alzheimer disease risk.
    Neurology. 2016 Dec 16. pii: 10.1212/WNL.0000000000003537.
    PubMed     Abstract available


    November 2016
  146. MOKRY LE, Ross S, Morris JA, Manousaki D, et al
    Genetically decreased vitamin D and risk of Alzheimer disease.
    Neurology. 2016 Nov 16. pii: 10.1212/WNL.0000000000003430.
    PubMed     Abstract available


  147. HOHMAN TJ, McLaren DG, Mormino EC, Gifford KA, et al
    Asymptomatic Alzheimer disease: Defining resilience.
    Neurology. 2016 Nov 4. pii: 10.1212/WNL.0000000000003397.
    PubMed     Abstract available


    October 2016
  148. KIKUCHI A, Okamura N, Hasegawa T, Harada R, et al
    In vivo visualization of tau deposits in corticobasal syndrome by 18F-THK5351 PET.
    Neurology. 2016 Oct 28. pii: 10.1212/WNL.0000000000003375.
    PubMed     Abstract available


  149. ZHAN X, Stamova B, Jin LW, DeCarli C, et al
    Gram-negative bacterial molecules associate with Alzheimer disease pathology.
    Neurology. 2016 Oct 26. pii: 10.1212/WNL.0000000000003391.
    PubMed     Abstract available


  150. WESTON PS, Nicholas JM, Lehmann M, Ryan NS, et al
    Presymptomatic cortical thinning in familial Alzheimer disease: A longitudinal MRI study.
    Neurology. 2016 Oct 12. pii: 10.1212/WNL.0000000000003322.
    PubMed     Abstract available


  151. MATTIS PJ, Niethammer M, Sako W, Tang CC, et al
    Distinct brain networks underlie cognitive dysfunction in Parkinson and Alzheimer diseases.
    Neurology. 2016 Oct 5. pii: 10.1212/WNL.0000000000003285.
    PubMed     Abstract available


    September 2016
  152. MATTSSON N, Zetterberg H, Janelidze S, Insel PS, et al
    Plasma tau in Alzheimer disease.
    Neurology. 2016 Sep 30. pii: 10.1212/WNL.0000000000003246.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Alzheimer's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: